<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380666</url>
  </required_header>
  <id_info>
    <org_study_id>20060021</org_study_id>
    <nct_id>NCT00380666</nct_id>
  </id_info>
  <brief_title>The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial evaluates the utility of 18FDG-PET/CT scan in the target definition process when&#xD;
      SBRT is planned for stage I NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial aims to evaluate the utility of 18FDG-PET/CT in SBRT planning for NSCLC with&#xD;
      particular emphasis on the definition of macroscopic and microscopic boundaries of malignant&#xD;
      growth. Studies indicate that the definition of the gross tumor volume may gain in quality&#xD;
      when CT and 18FDG-PET are combined. In about 30-60% of NSCLC patients considered for&#xD;
      radiotherapy, alteration of CT-based treatment volumes is the consequence of a supplementary&#xD;
      18FDG-PET scan. Studies examining the effect of combined PET/CT scans on the delineation of&#xD;
      the GTV generally show reduced intra- and inter-clinician variability. Whether this higher&#xD;
      degree of consistency is an actual improvement remains to be proven. Pathological specimens&#xD;
      from operated NSCLC patients may serve as a gold standard in this respect. To meet the need&#xD;
      for tight margins, the clinical target volume in SBRT planning is generally presumed to&#xD;
      correspond to the GTV. Whether this clinical practice rests on firm ground is also an issue&#xD;
      that can be addressed in a PET-CT-pathology correlation study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Technical problems.&#xD;
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance indices between CT-based and PET/CT-based target definitions versus volumes of surgical specimens</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra- and inter-individual variability of target definition</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>PET/CT defined target</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Target defined by use of fluoro-deoxy-glucose (FDG)-PET/CT scan for planning af stereotactic radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET/CT scan</intervention_name>
    <arm_group_label>PET/CT defined target</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or above&#xD;
&#xD;
          -  Histologically or cytologically verified NSCLC&#xD;
&#xD;
          -  Disease stage I (T1-2 N0 M0)&#xD;
&#xD;
          -  Referred from the multi-disciplinary lung cancer conference at Aarhus University&#xD;
             Hospital for operation at Skejby Hospital, Aarhus University Hospital&#xD;
&#xD;
          -  Oral and written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medically treated diabetes mellitus&#xD;
&#xD;
          -  Fasting blood-glucoses above 6,7 mM&#xD;
&#xD;
          -  Blood-creatinin above normal&#xD;
&#xD;
          -  Allergies to intravenous contrast&#xD;
&#xD;
          -  Detention according to the Danish laws on psychiatrics that does not comply with&#xD;
             participation in a clinical trial&#xD;
&#xD;
          -  Employment at the Dept. of Oncology, Aarhus University Hospital&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Hoyer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 25, 2006</study_first_submitted>
  <study_first_submitted_qc>September 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2006</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Morten HÃ¸yer</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

